Cancer gene panel test, US public insurance benefit approval

03

- Foundation Medicine's Cancer Gene Panel Test (F1CDx) approved by FDA & CMS simultaneously

- Rapid sales and share price rises in the future considering the case of Exact Sciences and the indication of F1CDx

- Recent FDA policy changes are likely to have a positive impact on domestic regulatory policy changes